Table. Detailed information of the reported studies associated with Pulmonary Enteric Adenocarcinoma.

Ref. (year)	Number of cases	Average age (year)	Gender/ Age (year)	Size (cm)/ Site	Immunohistochemical Results				Gene Mutation			Stage	Follow-up (month)	Treatment
					CK7	TTF-1	CK20	CDX2	EGFR	KRAS	Other			
Tsao et al. (1991)	1	40	M/40	2.0/RUL	NA	NA	NA	NA	NA	NA	NA	NA	A (48)	An uncomplicated right thoracotomy + wedge resection of the nodule
Weidner (1992)	1	44	F/44	NA	NA	NA	NA	NA	NA	NA	NA	NA	A(18)	NA
Yousem et al. (2005)	6	69.8	F/74	3.6/RUL	+	+	-	-	NA	NA	NA	T2N1M0	D(26)	Lobectomy with pneumonectomy in four + segmental resection in the remaining two
			F/70	1.7/RUL	+	+	-	-	NA	NA	NA	T2N1M0	D(18)	
			M/82	6.5/RUL	+	P+	-	-	NA	NA	NA	T2N0M0	D(5)	
			F/63	1.5/RUL	+	+	-	-	NA	NA	NA	T1N1M0	A(7)	
			F/73	7.0/LLL	+	+	-	-	NA	NA	NA	T2N1M0	A(3)	
			F/57	2.0/RUL	+	+	-	-	NA	NA	NA	T2N1M0	A(2)	
Inamura et al. (2005)	7	NA	M/NA	5.0/RUL	+	+	-	-	NA	NA	NA	T3N1M0	D(60)	NA
			M/NA	4.0/LUL	+	+	-	+	NA	NA	NA	T2N2M0	D(47)	
			F/NA	2.6/LLL	+	-	P+	P+	NA	NA	NA	T1N0M0	A(43)	
			M/NA	3.4/RLL	+	-	P+	P+	NA	NA	NA	T2N0M0	A(43)	
			M/NA	2.3/RLL	+	-	+	+	NA	NA	NA	T1N0M0	A(30)	
			M/NA	1.7/RLL	+	P+	-	P+	NA	NA	NA	T1N0M0	A(16)	
			M/NA	3.9/LUL	+	-	-	-	NA	NA	NA	T2N1M0	A(12)	
Satoh et al. (2005)	5	67	F/64	2.6/NA	NA	NA	NA	NA	NA	NA	NA	NA	A(36)	Lobectomy in four + partial resection in one
			M/72	3.4/NA	NA	NA	NA	NA	NA	NA	NA	NA	A(36)	
			M/73	2.3/NA	NA	NA	NA	NA	NA	NA	NA	NA	A(24)	
			M/51	1.7/NA	NA	NA	NA	NA	NA	NA	NA	NA	A(12)	
			M/77	3.9/NA	NA	NA	NA	NA	NA	NA	NA	NA	A(4)	
Maeda et al. (2007)	1	69	M/69	2.5/RLL	+	+	-	NA	NA	NA	NA	T1N0M0	NA	Right lower lobectomy + systemic lymph node dissection
Li et al. (2009)	1	51	F/51	3.3/LLL	-	-	+	+	NA	NA	NA	T2N1M0	A (10)	Left lower lobectomy + 4 cycles of adjuvant chemotherapy
Hatanaka et al. (2010)	1	51	F/51	1.0/RUL+3.0/LLL	-	-	+	+	NA	NA	NA	NA	A(48)	Partial resection of the RUL + left lower lobectomy
Lin et al. (2013)	1	61	F/61	5.0/RML	+	-	P+	-	NA	NA	NA	NA	A(6)	Right middle lobectomy
Qureshi et al. (2013)	1	61	F/61	Multiple bilateral	+	-	+	+	+	NA	NA	NA	NA	4 cycles of pemetrexed carboplatin
Laszlo et al (2014)	1	65	M/65	1.0/LUL	-	-	+	+	-	+	NA	NA	NA	Bisegmentectomy with standard hilar and mediastinal lymphadenectomy
Stojsic et al (2014)	2	25	M/24	6.0/LLL	-	-	+	+	-	+	NA	T2bN1M0	A(23)	(M)Left lower lobectomy with mediastinal lymphadenectomy (F)Resection of parietal pleura + partial resection of the callous 8th rib
			F/26	8.0/ Parietal pleura	-	-	+	+	-	-	NA	T3N0M0	A (31)	
Wang et al (2014)	9	60	M/65	2.3/RLL	+	F+	-	+	-	-	NA	T1N1M0	D(36)	Lobectomy in five + segmentectomy in two + pneumonectomy in two
			F/56	3.0/RUL	+	+	-	+	-	-	NA	T1N0M0	A(27)	
			M/60	3.5/RUL	+	+	-	+	-	-	NA	T2N0M0	A(39)	
			F/63	2.3/RUL	+	-	-	-	-	-	NA	T1N0M0	A(43)	
			F/65	2.0/RUL	+	+	-	-	-	-	NA	T2N1M0	D(12)	
			M/74	1.5/LLL	+	-	-	-	-	-	NA	T1N0M0	A(23)	
			M/61	6.0/RUL	+	-	F+	+	-	-	NA	T2N3M0	D(7)	
			F/34	4.8/RUL	+	-	-	+	-	-	NA	T2N1M0	A(22)	
			F/63	3.3/RUL	+	-	+	+	-	-	NA	T2N0M0	A(6)	

Metro et al (2015)	1	74	M/74	NA/RLL	+	-	-	+	-	+	NA	NA	D(5)	Radiation + systemic chemotherapy (3 cycles of gemcitabine + 2 cycles of pemetrexed)
Handa et al (2015)	1	70	M/70	3.0/RML	+	+	-	-	+	NA	NA	NA	NA	Right lower bilobectomy + systemic lymph node dissection + adjuvant chemotherapy (carboplatin and weekly paclitaxel)
Lin et al (2015)	1	53	F/53	Multiple bilateral	-	-	+	+	+	+	BRAF +	T2N1M1	A(12)	Chemotherapy (3 monthly cycles of XELOX + 4 monthly cycles of TP + 2 monthly cycles of FOLFIRI) + palliative surgery
Hammouni et al (2015)	1	50	M/50	3.5/RLL	+	+	-	-	NA	NA	NA	T2N0M0	A (15)	Right lower lobectomy with lymphadenectomy + chemotherapy
Garajova et al (2015)	3	70.3	M/68	3.5/RLL	+	-	-	+	-	+	NA	T2aN1M1	A(NA)	(M)Lobectomy + 2 cycles of XELOX + bisphosphonate + surgical removal of bone lesion + 4 cycles of carboplatin and pemetrexed + docetaxel. (F)Lobectomy + 6 cycles of carboplatin and pemetrexed + pemetrexed alone. (M)Died in 1 month
			F/71	NA/RLL	-	-	+	+	-	+	NA	T2aN0M1	A(NA)	
			M/72	NA	NA	NA	NA	NA	NA	+	NA	NA	D(1)	

Feng et al (2017)	30	NA	F(21) & M(9)/ NA	NA	NA	NA	+ 9/30	+ 6/30	+ 13/30	NA	NA	NA	NA	NA
Shoumura et al (2017)	1	59	M/59	NA/RLL	+	+	+	NA	NA	NA	NA	NA	NA	Right lower lobectomy
Sun et al (2017)	1	62	M/62	NA/RLL	+	-	-	+	NA	NA	NA	NA	NA	NA
Gomez-Hernandez (2017)	1	76	F/76	10.6/RLL	-	-	+	+	NA	NA	NA	NA	A(6)	Right lower lobectomy with lymph node dissection through muscle-sparing thoracotomy
Prakobkit et al (2017)	1	81	M/81	NA/LLL	+	+	F+	+	NA	NA	NA	NA	A(NA)	1 cycle of carboplatin and paclitaxel
Calio et al (2017)	7	NA	NA	NA	+ 7/7	+ 2/7	+ 2/7	+ 7/7	NA	NA	NA	NA	NA	NA
Nottegar et al (2017)	8	72	F(2) & M(6)/ NA	NA	+ 8/8	+ 1/8	NA	+ 8/8	-	+ 4/8	PIK3CA & ALK+ 1/8	NA	NA	NA
Matsushima et al (2017)	7	64.1	M/43	1.5/RLL 2.0/RLL	+/+	-/-	+/+	+/+	-/NA	-/NA	NA/NA	T1aN0M0	D(65)	Lobectomy
			F/71	11.5/LLL	+	-	+	+	-	-	NA	T3pN0M0	A(23)	
			M/77	4.6/RUL	+	-	+	-	-	-	NA	T2aN0M0	A(60)	
			M/58	4.9/LUL	-	-	-	+	+	-	NA	T2aN0M0	A(30)	
			F/70	4.0/LLL	+	-	+	+	-	-	NA	T2aN0M0	A(50)	
			M/73	8.3/LUL	+	-	+	-	-	-	NA	T3pN0M0	A(4)	
			M/67	1.6/RUL	+	+	-	-	NA	NA	NA	T1aN0M0	A(1)	

Zhao et al (2017)	28	64.8	F/69	2.5/RUL	+	+	-	-	-	-	NA	T3N2M0	D(19)	Lobectomy in twenty-four + segmentectomy in three + pneumonectomy in one
			F/45	5.5/RLL	+	-	-	+	-	-	NA	T2bN2	NA	
			M/69	5.5/RLL	+	-	-	+	-	-	NA	T2bN0	D(20)	
			M/68	7.0/RLL	-	-	-	+	-	-	NA	T2bN0	A(30)	
			M/67	4.5/RL	+	+	-	-	-	-	NA	T4N0	A(30)	
			M/70	2.5/LLL	+	+	-	-	+	-	NA	T1bN0	A(29)	
			M/72	3.5/LLL	+	P+	-	+	-	-	NA	T2aN2	D(13)	
			M/67	3.5/RLL	+	+	-	-	-	+	NA	T2aN0	NA	
			M/66	2.2/LUL	+	+	NA	+	-	-	NA	T1bN0	A(24)	
			M/56	1.8/LLL	+	+	-	-	-	-	NA	T1aN0M1a	A(21)	
			M/82	1.6/RUL	-	-	+	-	-	-	NA	T1aN0	A(21)	
			M/69	3.5/RUL	-	-	+	+	-	+	NA	T2aN2	D(1)	
			F/43	1.0/RLL	+	-	-	-	-	-	NA	T1aN0	A(19)	
			M/70	2.0/LUL	-	-	+	+	-	+	NA	T2aN0	A(13)	
			M/60	3.5/RML	-	-	+	+	-	+	NA	T2aN0	A(13)	
			M/66	2.2/LUL	-	-	-	+	-	+	NA	T1bN0	A(15)	
			M/58	2.0/LUL	+	-	-	+	-	-	NA	T1aN0	A(28)	
			M/63	4.2/RLL	+	-	P+	P+	-	-	NA	T2aN2	D(16)	
			M/65	3.0/LUL	+	+	-	-	+	-	NA	T1bN0	A(30)	
			M/71	3.0/RLL	-	-	+	+	-	-	NA	T1bN2	NA	
			F/63	5.0/LLL	+	-	-	-	-	+	NA	T2aN0	A(24)	
			M/55	6.0/LUL	NA	-	NA	-	-	-	NA	T2bN0	A(25)	
			M/59	2.2/RUL	-	-	+	P+	-	+	NA	T1bN0	NA	
			F/80	3.2/RUL	+	-	+	+	-	+	NA	T2aN0	A(31)	
			M/68	2.2/RUL	-	-	P+	+	-	+	NA	T1bN0	A(23)	
			F/60	3.5/LUL	+	+	-	-	+	-	NA	T2aN2	A(29)	
			M/72	6.0/LUL	+	+	-	-	-	+	NA	T2bN0	A(19)	
			M/62	3.5/LLL	+	-	-	+	-	-	NA	T2aN0	A(28)	

Bian et al (2017)	13	62.6	M/56	1.5/RUL	+	+	-	-	NA	NA	NA	T1aN0M0	A(12)	Segmentectomy in ten + aspiration biopsy in three
			F/53	2.0/RUL	+	+	-	-	NA	NA	NA	T1aN0M0	A(12)	
			M/80	0.8/LUL	+	-	-	-	NA	NA	NA	NA	D(8)	
			F/69	2.0/LLL	+	-	-	+	NA	NA	NA	T1aN0M0	A(6)	
			M/74	0.6/RUL	-	+	+	+	NA	NA	NA	NA	D(6)	
			M/56	3.5/RUL	+	-	+	+	NA	NA	NA	T2aN0M0	A(7)	
			F/47	5.0/LUL	+	+	+	-	NA	NA	NA	T2bN0M0	A(8)	
			F/59	3.0/LLL	-	-	+	+	NA	NA	NA	T2aN0M0	A(5)	
			M/61	11.0/RUL	-	+	+	+	NA	NA	NA	T3N0M0	D(8)	
			F/68	0.5/RUL	+	-	+	+	NA	NA	NA	NA	D(9)	
			F/60	4.5/LUL	+	+	+	+	NA	NA	NA	T2aN0M0	A(2)	
			M/77	3.0/RUL	+	-	-	+	NA	NA	NA	T1bN0M0	A(2)	
			F/54	2.5/LUL	+	+	+	-	NA	NA	NA	T2aN1M0	A(1)	
Hu et al (2018)	1	74	M/74	Multiple bilateral	+	-	+	+	NA	NA	NA	T4N2M0	NA	NA
Miyaoka (2018)	1	75	M/75	4.0/RLL	-	-	-	+	NA	NA	NA	NA	A(5)	Right lower lobectomy + 10 courses of chemotherapy
Miura et al (2018)	1	73	M/73	3.0/RLL	+	NA	+	+	NA	NA	NA	NA	D(8)	Right lower lobectomy + right upper lobe partial resection + ND2a-1
Iuppa Cister et al (2018)	15	66.9	M/78	NA/RUL	+	-	-	+	-	-	ERBB2+	NA	NA	Resection in seven
			M/54	NA/RUL	+	-	F+	+	-	-	TP53+	NA	NA	
			F/59	NA/RML	+	-	+	+	-	+	NA	NA	NA	
			F/48	NA/RLL	-	-	+	+	-	+	NA	NA	NA	
			M/74	NA/RUL	+	-	+	+	-	+	NA	NA	NA	
			M/51	NA/RML	+	-	-	+	-	-	TP53+	NA	NA	
			M/58	NA/NA	+	-	-	+	-	+	NA	NA	NA	
			F/81	NA/LUL	-	-	F+	+	-	-	NA	NA	NA	
			M/62	NA/RUL	+	-	-	+	-	+	NA	NA	NA	

			F/79	NA/LLL	+	-	-	+	-	+	NA	NA	NA		
			M/78	NA/RML	-	-	+	+	-	-	NA	NA	NA		
			M/65	NA/RLL	+	-	+	F+	-	+	TP53+	NA	NA		
			M/57	NA/RUL	-	-	-	+	-	+	NA	NA	NA		
			F/66	NA/RUL	+	-	+	+	-	+	TP53+	NA	NA		
			M/88	NA/RLL	+	F+	-	F+	-	-	NA	NA	NA		
Zhang et al (2018)	13	61.2	F(6)& M(7)/NA	NA	+ 13/13	+ 7/13	+ 7/13	+ 4/13	+ 5/13	+ 1/13	ERBB2 + 6/13	NA	NA	NA	
Nottegar et al (2018)	46	NA	NA	NA	+ 46/46	+ 21/46	+ 15/46	+ 46/46	+ 1/46	+ 28/46	ALK+ 6/46	NA	NA	NA	
Chen et al (2018)	18	63.2	F(12) & M(6) /NA	3.1/ RL(50%)+ LL(50%)	+ 16/18	+ 7/18	+ 17/18	+ 13/18	+ 1/5	+ 1/5	ERBB2 + 2/5	NA	A 13/18 (31) D 3/18 NA 2/18	NA	
Suzuki et al (2019)	1	50s	M/50s	NA/RUL	NA	NA	+	+	NA	NA	NA	T3N2 M1b	A(NA)	4 courses of chemotherapy (cisplatin + pemetrexed + bevacizumab)	
Gu et al (2019)[7]	15	59	F(6)& M(9) /NA	NA	+ 93%	+ 47%	+ 36%	+ 89%	+ 4%	+ 43%	NA	NA	NA	NA	
Total	252	63.94 11.5[b]	/	/	+ 169/197	+ 76/207	+ 100/219	+ 155/227	+ 27/169	+ 60/140	See in article	/	A 81/252 D 24/252 (20.1±15.1)[c] NA 147/252	/	

PXE: LOX: Oxaliplatin + capecitabine; TP: Paclitaxel + cisplatin; FOLFIRI: Irinotecan + leucovorin + 5-FU; DP: Docetaxel + cisplatin; NA: Not available; D: Died; A: Alive;

P: Partially; F: Focal; a)the study was not included in the analysis of positive rates about immunohistochemical results ,because this article did not provide exact number of positive results about each biomarker; b)the analysis of average age only covered most cases (n = 107)which provided exact number of age; c)the analysis of follow-up time only covered most cases (n = 85)which provided exact number of time.